Anti‐tumor effect of combination therapy with intratumoral controlled‐release paclitaxel (PACLIMER® microspheres) and radiation
The Prostate2003Vol. 58(3), pp. 291–298
Citations Over TimeTop 15% of 2003 papers
Rena G. Lapidus, Wenbin Dang, David M. Rosen, Alyssa M. Gady, Yelena Zabelinka, Robert N. O’Meally, Theodore L. DeWeese, Samuel R. Denmeade
Abstract
A controlled-release formulation of paclitaxel can be very effective in the treatment of prostate cancer. Additionally, PACLIMER Microspheres may be effectively used as a radiosensitizer in genitourinary cancers.
Related Papers
- → Preclinical Evaluation of Genexol-PM, a Nanoparticle Formulation of Paclitaxel, as a Novel Radiosensitizer for the Treatment of Non-Small Cell Lung Cancer(2013)249 cited
- → Preclinical evaluation of genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer.(2013)37 cited
- → Characterization of a novel metastatic prostate cancer cell line of LNCaP origin(2015)28 cited
- Establishment of androgen-independent human prostate cancer cell line model LNCaP-AI(2008)
- → Clinical study on the radiosensitizer of esophageal carcinoma(2015)